fluvoxamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1230 54739-18-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fluvoxamine
  • fluvoxamine maleate
  • depromel
A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS. Because of its high affinity at the sigma-1 receptor, the drug was evaluated whether could prevent clinical deterioration in patients with COVID-19. At the moment, there are insufficient data to recommend either for or against use of fluvoxamine for the treatment of COVID-19.
  • Molecular weight: 318.34
  • Formula: C15H21F3N2O2
  • CLOGP: 2.77
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 56.84
  • ALOGS: -4.64
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 14.87 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 13.46 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 53 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 23.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 31.95 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.20 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 12.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 5, 1994 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 220.90 19.82 178 5311 199443 50400192
Serotonin syndrome 129.48 19.82 60 5429 24653 50574982
Myoglobin urine present 128.28 19.82 24 5465 366 50599269
Intentional self-injury 111.46 19.82 53 5436 23059 50576576
Suicide attempt 100.16 19.82 65 5424 51667 50547968
Intentional overdose 86.76 19.82 64 5425 62440 50537195
Blood creatine phosphokinase increased 76.55 19.82 43 5446 26324 50573311
Toxicity to various agents 74.84 19.82 103 5386 212396 50387239
Toxic encephalopathy 68.97 19.82 25 5464 5490 50594145
Neuroleptic malignant syndrome 67.67 19.82 30 5459 11100 50588535
Amylase increased 65.62 19.82 24 5465 5406 50594229
Troponin increased 56.26 19.82 24 5465 8094 50591541
Drug abuse 48.76 19.82 45 5444 59801 50539834
Suicidal ideation 47.77 19.82 43 5446 55342 50544293
Blood lactate dehydrogenase increased 46.42 19.82 28 5461 19534 50580101
Blood potassium increased 45.57 19.82 26 5463 16372 50583263
Somnolence 45.49 19.82 69 5420 154916 50444719
Oscillopsia 42.21 19.82 8 5481 131 50599504
Schizophrenia 41.96 19.82 19 5470 7378 50592257
Mydriasis 41.14 19.82 21 5468 10606 50589029
Drug level increased 34.29 19.82 23 5466 19245 50580390
Galactorrhoea 32.55 19.82 13 5476 3710 50595925
Anxiety 31.09 19.82 63 5426 177543 50422092
Completed suicide 30.85 19.82 53 5436 131836 50467799
Alanine aminotransferase increased 28.27 19.82 41 5448 88318 50511317
Electrocardiogram QT prolonged 27.58 19.82 31 5458 51855 50547780
Obsessive-compulsive disorder 26.92 19.82 11 5478 3329 50596306
Overdose 25.88 19.82 42 5447 99685 50499950
Torsade de pointes 25.67 19.82 16 5473 11819 50587816
Tremor 25.34 19.82 45 5444 114858 50484777
Agitation 25.19 19.82 30 5459 53354 50546281
Sopor 24.53 19.82 19 5470 19860 50579775
Personality disorder 24.18 19.82 11 5478 4313 50595322
Alice in wonderland syndrome 23.85 19.82 4 5485 31 50599604
Drug screen false positive 23.66 19.82 7 5482 812 50598823
Akinesia 23.34 19.82 8 5481 1491 50598144
Restlessness 22.58 19.82 20 5469 25153 50574482
Anaemia folate deficiency 22.51 19.82 5 5484 184 50599451
Congestive cardiomyopathy 21.63 19.82 11 5478 5507 50594128
Mental disorder 20.79 19.82 18 5471 21973 50577662
Miosis 20.24 19.82 11 5478 6299 50593336

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Loss of libido 200.81 22.00 52 5197 2244 29567034
Apathy 150.08 22.00 52 5197 6119 29563159
Drug interaction 135.31 22.00 170 5079 197215 29372063
Psychotic disorder 129.73 22.00 66 5183 20288 29548990
Schizophrenia 128.14 22.00 47 5202 6518 29562760
Suicidal ideation 116.55 22.00 74 5175 34642 29534636
Serotonin syndrome 95.02 22.00 51 5198 17461 29551817
Persecutory delusion 80.10 22.00 25 5224 2116 29567162
Neuroleptic malignant syndrome 76.48 22.00 43 5206 16105 29553173
Encephalitis toxic 70.35 22.00 15 5234 272 29569006
Social avoidant behaviour 64.63 22.00 23 5226 2919 29566359
Weight increased 63.58 22.00 73 5176 76594 29492684
Sedation 63.10 22.00 39 5210 17366 29551912
Suicide attempt 57.61 22.00 48 5201 34062 29535216
Intentional overdose 52.54 22.00 48 5201 38480 29530798
Catatonia 51.94 22.00 22 5227 4446 29564832
Depression 51.17 22.00 69 5180 85078 29484200
Overdose 48.44 22.00 65 5184 79754 29489524
Salivary hypersecretion 47.07 22.00 24 5225 7385 29561893
Delirium 45.91 22.00 45 5204 39352 29529926
Antipsychotic drug level increased 44.57 22.00 18 5231 3225 29566053
Mental impairment 39.65 22.00 23 5226 9118 29560160
Drug level increased 39.31 22.00 30 5219 18757 29550521
Cardiac dysfunction 39.21 22.00 14 5235 1793 29567485
Aggression 38.46 22.00 39 5210 35502 29533776
Sopor 38.35 22.00 24 5225 10910 29558368
Sexual relationship change 37.77 22.00 6 5243 17 29569261
Toxicity to various agents 37.60 22.00 90 5159 173571 29395707
Enuresis 37.26 22.00 14 5235 2070 29567208
Completed suicide 34.12 22.00 59 5190 90187 29479091
Hanging 33.25 22.00 7 5242 119 29569159
Obsessive-compulsive disorder 32.52 22.00 16 5233 4560 29564718
Respiratory fatigue 30.93 22.00 6 5243 66 29569212
Obsessive thoughts 30.73 22.00 9 5240 613 29568665
Coma scale abnormal 30.37 22.00 14 5235 3455 29565823
Cyclothymic disorder 29.59 22.00 6 5243 84 29569194
Antipsychotic drug level above therapeutic 29.56 22.00 10 5239 1091 29568187
Premature ejaculation 27.58 22.00 6 5243 120 29569158
Neonatal behavioural syndrome 27.48 22.00 6 5243 122 29569156
Anxiety 27.41 22.00 52 5197 85313 29483965
Akathisia 26.71 22.00 16 5233 6726 29562552
Distributive shock 26.65 22.00 9 5240 976 29568302
Bradycardia 26.23 22.00 44 5205 65585 29503693
Motor developmental delay 25.91 22.00 8 5241 652 29568626
Genital pain 25.06 22.00 6 5243 186 29569092
Orthostatic hypotension 24.77 22.00 25 5224 22604 29546674
Tic 24.58 22.00 10 5239 1825 29567453
Genital hypoaesthesia 24.47 22.00 6 5243 206 29569072
Brain injury 24.25 22.00 14 5235 5498 29563780
Somnolence 23.94 22.00 52 5197 93903 29475375
Heat stroke 23.40 22.00 8 5241 901 29568377
Agitation 22.66 22.00 36 5213 51268 29518010
Tardive dyskinesia 22.19 22.00 13 5236 5245 29564033
Hypothermia 22.11 22.00 16 5233 9223 29560055

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 291.86 18.06 305 8894 361778 64127755
Serotonin syndrome 211.82 18.06 106 9093 39176 64450357
Intentional overdose 133.28 18.06 107 9092 89837 64399696
Suicide attempt 132.71 18.06 97 9102 70910 64418623
Neuroleptic malignant syndrome 113.13 18.06 60 9139 24936 64464597
Intentional self-injury 112.81 18.06 63 9136 28981 64460552
Myoglobin urine present 111.79 18.06 24 9175 566 64488967
Toxicity to various agents 99.32 18.06 182 9017 363331 64126202
Suicidal ideation 96.05 18.06 78 9121 66464 64423069
Loss of libido 95.66 18.06 28 9171 2376 64487157
Apathy 77.71 18.06 36 9163 11196 64478337
Blood creatine phosphokinase increased 74.85 18.06 64 9135 58494 64431039
Psychotic disorder 73.19 18.06 51 9148 34527 64455006
Schizophrenia 68.67 18.06 33 9166 11135 64478398
Encephalitis toxic 67.55 18.06 14 9185 277 64489256
Catatonia 67.37 18.06 29 9170 7591 64481942
Overdose 62.36 18.06 94 9105 159472 64330061
Completed suicide 59.39 18.06 111 9088 224303 64265230
Somnolence 56.73 18.06 103 9096 203542 64285991
Sopor 54.16 18.06 40 9159 29621 64459912
Troponin increased 53.31 18.06 31 9168 15368 64474165
Drug level increased 51.24 18.06 41 9158 34155 64455378
Anxiety 47.19 18.06 95 9104 202554 64286979
Sedation 46.32 18.06 42 9157 41420 64448113
Toxic encephalopathy 45.63 18.06 24 9175 9791 64479742
Obsessive-compulsive disorder 44.78 18.06 19 9180 4799 64484734
Salivary hypersecretion 43.56 18.06 25 9174 12088 64477445
Amylase increased 43.09 18.06 23 9176 9662 64479871
Tremor 42.55 18.06 76 9123 148154 64341379
Drug abuse 42.07 18.06 71 9128 132303 64357230
Agitation 41.73 18.06 57 9142 88310 64401223
Aggression 40.58 18.06 41 9158 46191 64443342
Oscillopsia 37.79 18.06 8 9191 176 64489357
Obsessive thoughts 36.77 18.06 11 9188 1006 64488527
Akathisia 36.76 18.06 22 9177 11488 64478045
Enuresis 36.26 18.06 14 9185 2776 64486757
Hanging 35.79 18.06 7 9192 102 64489431
Mental impairment 34.32 18.06 24 9175 16319 64473214
Galactorrhoea 34.32 18.06 14 9185 3205 64486328
Sexual relationship change 32.88 18.06 5 9194 13 64489520
Cardiac dysfunction 31.38 18.06 13 9186 3093 64486440
Cyclothymic disorder 31.11 18.06 7 9192 206 64489327
Antipsychotic drug level increased 31.09 18.06 15 9184 5100 64484433
Blood potassium increased 30.36 18.06 27 9172 25953 64463580
Mydriasis 28.74 18.06 21 9178 15291 64474242
Blood lactate dehydrogenase increased 28.41 18.06 29 9170 33049 64456484
Dyspnoea 28.03 18.06 37 9162 718637 63770896
Rhabdomyolysis 27.55 18.06 48 9151 91678 64397855
Delirium 27.31 18.06 41 9158 69153 64420380
Gaze palsy 26.87 18.06 11 9188 2539 64486994
Antipsychotic drug level above therapeutic 26.56 18.06 10 9189 1851 64487682
Distributive shock 26.49 18.06 10 9189 1865 64487668
Extrapyramidal disorder 26.25 18.06 22 9177 19530 64470003
Semen volume decreased 26.24 18.06 5 9194 63 64489470
Premature ejaculation 26.02 18.06 5 9194 66 64489467
Respiratory fatigue 25.61 18.06 6 9193 212 64489321
Activation syndrome 24.31 18.06 6 9193 265 64489268
Pain 24.22 18.06 26 9173 553485 63936048
Inappropriate antidiuretic hormone secretion 23.76 18.06 22 9177 22267 64467266
Mania 23.27 18.06 19 9180 16267 64473266
Weight increased 23.20 18.06 75 9124 213273 64276260
Coma scale abnormal 22.62 18.06 14 9185 7760 64481773
Arthralgia 22.62 18.06 18 9181 442242 64047291
Orgasmic sensation decreased 21.93 18.06 4 9195 39 64489494
Brain injury 21.78 18.06 15 9184 9950 64479583
Acanthosis nigricans 21.76 18.06 5 9194 162 64489371
Genital hypoaesthesia 21.56 18.06 5 9194 169 64489364
Alice in wonderland syndrome 21.49 18.06 4 9195 44 64489489
Depressed level of consciousness 21.12 18.06 40 9159 81396 64408137
Parkinsonism 21.02 18.06 17 9182 14356 64475177
Restlessness 20.82 18.06 27 9172 39758 64449775
Orthostatic hypotension 20.33 18.06 29 9170 46709 64442824
Drug screen false positive 20.32 18.06 7 9192 1005 64488528
Bradycardia 20.19 18.06 49 9150 118170 64371363
Anaemia folate deficiency 19.75 18.06 5 9194 245 64489288
Myoclonus 19.74 18.06 21 9178 25097 64464436
Psychomotor skills impaired 19.59 18.06 10 9189 3835 64485698
Respiratory depression 19.13 18.06 20 9179 23423 64466110
Aspiration of gastric residual 18.74 18.06 3 9196 12 64489521
Altered state of consciousness 18.71 18.06 25 9174 37877 64451656
Akinesia 18.63 18.06 9 9190 3070 64486463
Negativism 18.19 18.06 6 9193 754 64488779
Electrocardiogram QT prolonged 18.15 18.06 37 9162 79411 64410122

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AB08 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Selective serotonin reuptake inhibitors
FDA MoA N0000000109 Serotonin Uptake Inhibitors
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:50949 SSRI
FDA EPC N0000175696 Serotonin Reuptake Inhibitor
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D000928 Antidepressive Agents
MeSH PA D018687 Antidepressive Agents, Second-Generation
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D065609 Cytochrome P-450 CYP1A2 Inhibitors
MeSH PA D065689 Cytochrome P-450 CYP2C19 Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018490 Serotonin Agents
MeSH PA D017367 Serotonin Uptake Inhibitors
MeSH PA D014149 Tranquilizing Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Social phobia indication 25501002 DOID:11257
Obsessive-compulsive disorder indication 191736004 DOID:10933
Depressive disorder off-label use 35489007
Posttraumatic stress disorder off-label use 47505003 DOID:2055
Bipolar affective disorder, current episode depression off-label use 191627008 DOID:3312
Suicidal thoughts contraindication 6471006
Bipolar disorder contraindication 13746004 DOID:3312
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Upper gastrointestinal hemorrhage contraindication 37372002
Syndrome of inappropriate vasopressin secretion contraindication 55004003 DOID:3401
Blood coagulation disorder contraindication 64779008 DOID:1247
Epilepsy contraindication 84757009 DOID:1826
Hyponatremia contraindication 89627008
Mania contraindication 231494001
Hypomania contraindication 231496004
Disease of liver contraindication 235856003 DOID:409
Serotonin syndrome contraindication 371089000
Breastfeeding (mother) contraindication 413712001
Poor metabolizer due to cytochrome p450 CYP2D6 variant contraindication 423629005
Smokes tobacco daily contraindication 449868002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.36 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 8.51 WOMBAT-PK CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 5.95 PDSP
Sodium-dependent dopamine transporter Transporter Ki 8.84 CHEMBL
Cytochrome P450 1A2 Enzyme Ki 5.07 WOMBAT-PK
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.44 CHEMBL
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 8.19 IUPHAR
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.44 CHEMBL
Sigma intracellular receptor 2 Unclassified Ki 5.07 CHEMBL

External reference:

IDSource
4023976 VUID
N0000021981 NUI
D00824 KEGG_DRUG
61718-82-9 SECONDARY_CAS_RN
4020892 VANDF
4023976 VANDF
C0085228 UMLSCUI
CHEBI:5138 CHEBI
FVX PDB_CHEM_ID
CHEMBL814 ChEMBL_ID
DB00176 DRUGBANK_ID
CHEMBL1409 ChEMBL_ID
D016666 MESH_DESCRIPTOR_UI
5324346 PUBCHEM_CID
7189 IUPHAR_LIGAND_ID
3879 INN_ID
O4L1XPO44W UNII
203143 RXNORM
40916 MMSL
4758 MMSL
d03804 MMSL
003633 NDDF
003634 NDDF
116522003 SNOMEDCT_US
372905008 SNOMEDCT_US
96213009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0228-2848 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 21 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0228-2849 CAPSULE, EXTENDED RELEASE 150 mg ORAL ANDA 21 sections
Fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1670 TABLET, FILM COATED 25 mg ORAL ANDA 34 sections
Fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1671 TABLET, FILM COATED 50 mg ORAL ANDA 34 sections
Fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1672 TABLET, FILM COATED 100 mg ORAL ANDA 34 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 10370-175 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 10370-176 CAPSULE, EXTENDED RELEASE 150 mg ORAL ANDA 30 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 16590-270 TABLET 25 mg ORAL NDA 11 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 33261-683 TABLET, COATED 50 mg ORAL NDA AUTHORIZED GENERIC 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 50090-5988 TABLET, COATED 100 mg ORAL NDA authorized generic 31 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 60505-0164 TABLET 25 mg ORAL ANDA 32 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 60505-0165 TABLET 50 mg ORAL ANDA 32 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 60505-0166 TABLET 100 mg ORAL ANDA 32 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 62559-158 TABLET, COATED 25 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 62559-159 TABLET, COATED 50 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 62559-160 TABLET, COATED 100 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 63629-8018 TABLET, COATED 25 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 68071-2337 TABLET, COATED 50 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 68151-0637 TABLET, COATED 50 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 68788-7219 TABLET, COATED 100 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 68788-7219 TABLET, COATED 100 mg ORAL NDA authorized generic 31 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 68788-8175 TABLET 100 mg ORAL ANDA 32 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 69452-182 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 22 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 69452-183 CAPSULE, EXTENDED RELEASE 150 mg ORAL ANDA 22 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 70518-1057 TABLET, COATED 100 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 70518-1643 TABLET, COATED 50 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 70518-1789 TABLET, COATED 25 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 70518-1789 TABLET, COATED 25 mg ORAL NDA authorized generic 31 sections
Fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 70518-3153 TABLET, FILM COATED 50 mg ORAL ANDA 33 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 71335-0264 TABLET, COATED 100 mg ORAL NDA authorized generic 31 sections